Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot...

Full description

Bibliographic Details
Main Authors: Roberta Antonia Diotti, Ruggero Capra, Lucia Moiola, Valeria Caputo, Nicola De Rossi, Francesca Sangalli, Vittorio Martinelli, Roberto Burioni, Massimo Clementi, Nicasio Mancini
Format: Article
Language:English
Published: MDPI AG 2016-05-01
Series:Viruses
Subjects:
multiple sclerosis
natalizumab
progressive multifocal leukoencephalopathy
humoral response
Online Access:http://www.mdpi.com/1999-4915/8/5/128

Internet

http://www.mdpi.com/1999-4915/8/5/128

Similar Items